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Abstract
Summary We studied new users of oral bisphosphonates
and found that less than half persisted with therapy for
2 years, and interruptions in use were common. During a
median observation period of 4.7 years, 10% of patients
filled only a single prescription, 37% switched therapies
and median cumulative exposure was 2.2 years.
Introduction We sought to describe bisphosphonate pre-
scribing, persistence and cumulative exposure among
seniors in Ontario, Canada.
Methods We used Ontario Drug Benefit pharmacy claims
to identify residents aged≥66 years who initiated oral
bisphosphonate therapy between April 1996 and March
2009. The first date of bisphosphonate dispensing was
considered the index date. Persistence with therapy was
defined as continuous treatment with no interruption
exceeding 60 days. We examined persistence with therapy
and the number of extended gaps (>60 days) between
prescriptions over time periods ranging from 1 to 9 years.
We also identified the proportion of patients filling only a
single prescription and switching to a different bisphosph-
onate, and calculated the median days of exposure
irrespective of gaps in therapy.
Results A total of 451,113 eligible new bisphosphonate users
wereidentified:meanage=75.6years(SD=6.9),84%female,
and median follow-up length=4.7 years. Persistence with
therapy declined from 63% at 1 year to 46% at 2 years and
12%at9years.Amongthosewithatleast5yearsoffollow-up
(n=213,029), 61% had one or more extended gaps in
bisphosphonate therapy. Overall, 10% of patients filled only
a single prescription, 37% switched to a different bisphosph-
onate and the median exposure was 2.2 years.
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Osteoporos Int (2012) 23:1075–1082
DOI 10.1007/s00198-011-1645-7Conclusion Less than half of patients persisted with
bisphosphonate therapy for 2 years and interruptions in
therapy were common, with most patients experiencing two
or more >60-day gaps in therapy. Interventions are needed
to improve persistence with bisphosphonate therapy and




Osteoporosis is a major public health concern that
results in considerable fracture-related morbidity and
mortality [1–3]. In Canada, oral bisphosphonates (alendr-
onate, etidronate, and risedronate) are the most commonly
prescribed agents for treating osteoporosis and preventing
fractures [3, 4]. However, persistence with therapy is
suboptimal and linked to reduced drug effectiveness [5–
8]. Prior systematic reviews document that fewer than
half of patients persist with osteoporosis treatment for a
full year [5, 9, 10], with estimates ranging between 18%
and 78% for bisphosphonates [11, 12]. An underreported
finding is that many patients who discontinue bisphosph-
onate therapy reinitiate treatment after an extended gap
[13]. To further explore this issue, we studied all new
users of oral bisphosphonates among older adults in
Ontario from April 1996 to March 2009. We hypothesized
that the majority of patients would discontinue treatment,
yet a significant proportion wo u l dr e t u r nt ot h e r a p ya f t e r
an extended gap in therapy. We also hypothesized that
many patients would experience more than one extended
gap in therapy, yet cumulative exposure to oral




We used Ontario healthcare utilization (medical and
pharmacy) databases to identify, characterize and follow
all new users of oral bisphosphonates aged 66 or more
years in Ontario since 1996. Ontario medical and pharmacy
claims databases are widely used for research purposes, and
several studies demonstrate data quality [14–18]. Medicare
services are funded through comprehensive universal health
insurance for all Canadian residents, and residents of
Ontario aged 65 or more years qualify for pharmacy
coverage through the Ontario Drug Benefit (ODB) program
[19]. The ODB Formulary has included unrestricted access
to cyclical etidronate since 1996 and alendronate and
risedronate since 2007.
Study cohort
We identified new users of alendronate (5, 10, and
70 mg), cyclical etidronate and risedronate (5 and
35 mg) using ODB program data from April 1, 1996 to
March 31, 2009. The first date of bisphosphonate
dispensing over the entire study period was considered
the index date. To ensure a minimum 1 full year of
pharmacy claims history, we restricted inclusion to those
aged 66 years or older at index date. We also excluded
patients with Paget’s disease diagnosis and patients with
any prescription related to osteoporosis (bisphosphonate,
calcitonin, raloxifene, or teriparatide) in the year prior to
the index date. For descriptive purposes, we defined age
at index, and identified bone mineral density (BMD)
testing, and fracture history within 1 year prior to the
index date (Appendix 1). BMD testing was identified
using billing codes for Dual-Photon Absorptiometry
(DPA) prior to 1998 and Dual-energy X-ray Absorptiom-
etry (DXA) from 1998 to 2009. These codes have an
estimated sensitivity of 98% and specificity of 93% for
identifying BMD testing in Ontario [18]. Fractures were
identified using outpatient and inpatient billing claims.
Prior to April 2002, inpatient diagnoses were coded using
ICD ninth revision, clinical modification (ICD-9-CM).
Since then, the Canadian tenth revision (ICD-10-CA)
codes have been used.
Measuring persistence with therapy
We determined persistence with therapy using ODB
(pharmacy claims) data. ODB data include the days
supplied and thus we can calculate when a patient is
expected to refill their prescription. We defined persis-
tence as continuous treatment without an interruption
(gap) exceeding 60 days (Fig. 1). In a secondary
analysis, we extended the permissible gap length to
120 days. These gap lengths are consistent and compara-
ble with prior research on persistence with osteoporosis
pharmacotherapy [20–23]. When calculating persistence,
overlap of the same drug and regimen was additive;
however, a switch between agents or from daily to weekly
dosing of the same drug was considered continuous use
with no overlap granted. Values for missing days supplied
were imputed prior to 1997 when this field was not
reported in the ODB database; this included 13 patients
dispensed alendronate (24 dispensing records), and all
patients dispensed cyclical etidronate prior to 1997. We
imputed a 60-day supply for alendronate—the median
number of days supply for alendronate from 1997 to
1076 Osteoporos Int (2012) 23:1075–10821999. A 90-day supply was imputed for cyclical etidronate
since it is dispensed as 14 days of active drug plus 76 days of
calcium supplements.
Statistical analysis
We compared the characteristics (age, sex, bisphospho-
nate at index, prior BMD testing, and fracture history)
of new users across four time periods: April 1996–
March 2000, April 2000–March 2003, April 2003–
March 2006, and April 2006–March 2008. We then
examined persistence with therapy and number of
extended gaps (primary analysis gap length >60 days
and secondary analysis gap length >120 days) between
prescriptions according to follow-up periods ranging
f r o m1t o9y e a r sa f t e rt r e a t m ent initiation. Only those
persons with complete follow-up information were
included in each respective follow-up period, and
therefore patients who died within the observation
period were excluded from respective analyses. In a
secondary analysis, we examine the length of time until
return to therapy following a 120-day gap or longer by
plotting a Kaplan–Meier curve that censored patients at
time of death, emigration from the province or March
31, 2009—the last date of available data. Finally, we
calculated the proportion of patients that filled only a
single prescription, the proportion that switched to a
different bisphosphonate, and the median days of




We identified 451,113 new bisphosphonate users meeting
our inclusion criteria. Of these, 84% were female and the
mean age was 75.6 years (SD=6.9). From April 2000 to
March 2009 fiscal year groups, we found that the
proportion of male users increased over time (from
8.9% to 23.6%), etidronate use at index declined over
time (from 91.0% to 22.5%), and BMD testing prior to
treatment initiation has been stable at 63% since 2000
(Table 1).
Persistence with bisphosphonate therapy
A summary of persistence with bisphosphonate therapy
over time is provided in Table 2. In our primary analysis
that used a 60-day permissible gap, we identified that the
proportion of patients that persisted with therapy declined
from 63% at 1 year to 12% after 9 years. We also
identified that most patients experienced one or more
extended gaps in bisphosphonate therapy. For example,
among the 213,029 new users with at least 5 years of
follow-up, 25% persisted with therapy for the full 5 years,
61% experienced one (24%) or more (37%) extended gaps
in therapy, and 14% discontinued treatment without
returning to bisphosphonate therapy. Using a more lenient
120-day permissible gap to define non-persistence, we
note that persistence rates increased and fewer users were
identified to have experienced extended gaps in drug
therapy. For example, persistence at 1 year increased from
63% using a 60-day permissible gap to 77% when using a
120-day permissible gap (Table 2). Figure 2 represents the
Kaplan–Meier curve for time until treatment reinitiation
after at least 120 days without drug, that censors on date
of death, and loss to follow-up. Here we note that 38% of
patients returned to therapy within 1 year, 51% returned
within 2 years, and 67% returned to therapy within
5y e a r s .
Number of prescriptions, total drug exposure and drug
switching
Patients were followed for a median length of 4.7 years
(min=0.5 years, max=12.8 years). During the first year of
Rx 1  Rx n+1 
Extended Gap (> 60 or 120 days)
Rx 2  Rx n 
Theoretical End Date Restart Date** 
≤60 or 120 days*  
Index Date (Initiation) 
Fig. 1 Defining persistence with therapy (adapted from Cadarette et
al. [33]). Persistence with therapy after index was defined as
continuous treatment without a gap >60 days (primary analysis)
and >120 days (secondary analysis). Theoretical end of treatment
must have occurred within the follow-up interval under investiga-
tion; however, pharmacy data after the theoretical treatment end
date were used to identify whether or not an extended gap was
relevant to define non-persistence. *If the gap length between
prescriptions was ≤60 days, then the patient was assumed to have
persisted with therapy. **Example when a patient reinitiates
therapy after an extended gap. Some patients never reinitiate
treatment and are defined in Table 2 as having discontinued
therapy. Rx = Prescription
Osteoporos Int (2012) 23:1075–1082 1077therapy, 16% of users received only a single prescription of
an oral bisphosphonate; however, this decreased to 10%
when considering the entire follow-up period of up to
12.8 years. The median length of time covered by
bisphosphonates before a period greater than 60 days
without treatment was 0.9 years (SD=2.5 years), and this
increased to 2.2 years (SD=2.8 years) when considering all
episodes of use.
We found that 7% of new bisphosphonate users
switched to a different bisphosphonate within 1 year of
treatment initiation, and this increased to more than a
third of patients (37%) over the entire duration of follow-up.
Although fewer than 8% of etidronate users who initiated
therapy between 1996 and 2003 switched to a different
bisphosphonate within the first year of therapy, this
increased to 51% over the entire follow-up period of up
Table 2 Proportion of new oral bisphosphonate
a users who persisted
b with therapy, discontinued therapy
c and experience one or more extended
gaps in treatment
Follow-up years 12345678 9
N
d 402,791 350,983 302,444 257,029 213,029 171,515 134,098 99,118 68,453
60-day permissible gap
Persisted with therapy
b 63.1 46.4 36.8 30.1 25.0 20.9 17.6 14.8 12.2
Discontinued therapy
c 15.2 15.8 15.3 14.6 14.0 13.4 12.7 12.0 11.4
Reinitiated therapy 21.7 37.8 47.9 55.3 61.0 65.7 69.7 73.2 76.4
One extended gap 16.7 23.2 24.5 24.7 24.3 23.6 22.9 21.9 20.7
≥2 extended gaps 5.0 14.6 23.4 30.6 36.7 42.1 46.8 51.3 55.7
120-day permissible gap
Persisted with therapy
b 76.7 63.5 54.8 48.1 42.7 38.0 34.4 30.8 27.4
Discontinued therapy
c 16.8 18.6 18.7 18.6 18.3 18.0 17.5 17.4 16.9
Reinitiated therapy 6.5 17.9 26.5 33.3 39.0 44.0 48.1 51.8 55.7
One extended gap 6.4 15.9 20.6 23.3 25.0 26.2 27.0 27.4 27.9
≥2 extended gaps 0.1 2.0 5.9 10.0 14.0 17.8 21.1 24.4 27.8
aAlendronate (5, 10, and 70 mg), cyclical etidronate, risedronate (5 and 35 mg) identified from the Ontario Drug Benefit (ODB) program data,
residents aged 66 or more years. First dispensing over entire period from April 1996 to March 2009 was considered the index date.
bPersistence with therapy after index was defined as continuous treatment without a permissible gap.
cIdentified as the proportion of patients who did not persist with therapy, and did not reinitiate treatment in the respective follow-up period.
dNumber of patients with complete follow-up data included and thus excludes those who died, moved out of the province, and if March 31, 2009
occurred within the follow-up period. Proportions therefore cannot be compared directly over time.
Table 1 Characteristics of new users of oral bisphosphonates










N=106,456 N=119,468 N=119,326 N=105,863 N=451,113
Age, mean (SD) 75.1 (6.4) 75.4 (6.7) 76.0 (7.1) 75.6 (7.2) 75.6 (6.9)
Males,% 8.9 13.3 19.8 23.6 16.4
Etidronate,% 91.0 89.5 55.3 22.5 65.1
BMD test,%
b 58.1 63.6 63.3 63.2 62.1
Fracture history,%
c
Thoracic vertebral 0.1 0.2 0.2 0.2 0.2
Hip, humerus, radius/ulna 5.4 5.5 6.2 6.5 5.9
aAlendronate (5, 10, and 70 mg), cyclical etidronate and risedronate (5 and 35 mg).
bBMD testing identified within 1 year prior to index date using Ontario Health Insurance Plan (OHIP) billing codes for dual photon
absorptiometry (DPA) prior to 1998, and dual-energy X-ray absorptometry (DXA) from 1998 to 2009 (see Appendix 1).
cFractures were identified using ICD-9-CM codes before April 2002, and ICD-10-CA codes since April 2002 (see Appendix 1).
1078 Osteoporos Int (2012) 23:1075–1082to 12.8 years. Among new users treated with alendronate
or risedronate at the index date, only 5% switched
therapy within one year and less than 10% switched
over the length of follow-up.
Discussion
Our results are consistent with prior reports that indicate
that persistence with bisphosphonate therapy is suboptimal
[10–12]. Recent evidence suggests that uninterrupted
bisphosphonate therapy for a minimum of 3–5 years is
important to reduce fracture risk [24–27]. However, our
results show that fewer than half of patients persist with
therapy for 2 years, and only 25% persist with therapy for
5 years. Even when a more lenient permissible gap of
120 days was used to identify non-persistence, our findings
identify that only 40% of patients persisted with therapy for
5 years. We also note that extending the permissible gap
length from 60 to 120 days changed our estimates of
persistence from 63% to 77% at 1 year, and from 25% to
43% at 5 years. These findings highlight the impact of
length of follow-up and permissible gap on persistence
measurement. Given the observed variation in persistence
rates with different permissible gap lengths, we recommend
that methodology be explicitly reported to facilitate study
comparisons [13].
Regardless of the permissible gap length used to
determine length of treatment persistence, our findings
identify that extended gaps in oral bisphosphonate therapy
are common, and the majority of patients experience more
than one extended gap between bisphosphonate prescrip-
tions. Although it is encouraging that many patients are
returning to therapy, the clinical impact of the time off drug
remains unknown, and requires further investigation. In
fact, experiencing a fracture after stopping osteoporosis
treatment has been found to be a significant predictor of
reinitiating osteoporosis medication [20].
Our results also indicate that the longer the length of
follow-up, the more likely it is that a patient will switch
treatments. Over the entire study period of up to 12.8 years,
37% of all users (51% of etidronate users) switched to a
different oral bisphosphonate. In Ontario, etidronate has been
available without restriction through the ODB program since
1996, thus permitting greater opportunity for patients to
initiate etidronate and switch to another bisphosphonate over
time. Although second generation bisphosphonates have been
available since 1996 (daily alendronate), the initial listing
status for both alendronate and risedronate required a trial of,
or documented allergy to etidronate (2000–2003), or two of
the following: (i) BMD T-score ≤3.0 SD, (ii) aged 75 or more
years, (iii) prior osteoporosis-related fracture (2003–2007).
Since 2007, all three agents have been covered without
restrictions. Given that clinical trial data demonstrate reduc-
tions in non-vertebral fracture risk compared to placebo with
use of alendronate and risedronate, but not etidronate [2, 28],
it is not surprising that patients were observed to have
switched from etidronate to alendronate or risedronate after
treatment failure, or once access to these drugs through the
ODB program became less restrictive. We identified that less
than 10% of alendronate/risedronate users switched to a
different bisphosphonate over follow-up, compared to 51%
of etidronate users. Switching rates between bisphosphonates
may be lower in regions such as the United States, where
etidronate is not available.
Despite the decline in etidronate prescribing over time
and the noted increase in the number of males being
treated, we found little change over time in the percent
of new users having had a BMD test or fracture. The
slight increase in BMD testing seen between April 1996–
March 2000 and April 2000–March 2003 is likely
attributable to the switch from DPA to DXA technology
in 1998 and the increased number of DXA machines,
from 95 in 1997 to 213 in 1998 [29]. Similarly, the slight
increase in the proportion with hip, humerus or radius/ulna
fracture within the year prior to index is likely related to
the change in coding from ICD-9-CM to ICD-10-CA that
occurred in 2002. While ICD-10-CA includes greater
specification, previous studies have found sensitivity of
95% or higher for the identification of fractures using
ICD-9-CM [30], and ICD-10-CA coding [17]. Our results
therefore suggest little change in the importance of BMD
testing or fracture history in guiding bisphosphonate
therapy over our study period.
Three important study limitations are worth noting. First,
we were unable to study patterns of bisphosphonate therapy
among persons younger than 66 years. It is possible that
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Fig. 2 Time until return to oral bisphosphonate therapy following a
period of 120 days or longer without treatment among new users in
Ontario aged 66 or more years, April 1996–March 2009
Osteoporos Int (2012) 23:1075–1082 1079we were unable to observed, such as prescribing pharma-
cotherapy at younger ages and prior to 66 years. It is also
possible that some of the identified “new users” were
prevalent users with private drug coverage that switched to
coverage under the ODB program once these agents were
covered by the public plan. However, recent data suggest
good agreement between self-report and ODB pharmacy data
for bisphosphonate use among older women (kappa statistic=
0.81, 95% CI=0.77–0.85 [18]), and few seniors in Ontario
do not access medications through the ODB program [14].
Second, we restricted our study to oral bisphosphonates,
and thus it is possible that some users classified as non-
persistent with therapy may have switched to non-oral
bisphosphonate therapy, such as calcitonin, raloxifene, ter-
iparatide, or zoledronic acid. However, we expect this to have
occurred in only a few patients, as calcitonin and teriparatide
are not listed on the ODB formulary, and raloxifene and
zoledronic acid are only available under restricted conditions.
Forexample,zoledronicacidisonlyavailableamongmenand
women unable to take oral medications. In addition, prior
research has identified that those who return to osteoporosis
therapy after an extended gap tend to return to the same drug
class [20]. Thus, while we recognize that switching between
osteoporosis therapies may be more common in regions with
better access to non-bisphosphonate therapy, we expect this
to be minimal in our sample. Further research using large
claims databases in other regions will help clarify switching
patterns.
Third, we recognize that some of our observed non-
persistence may have been physician directed due to the
experience of, or concern for adverse drug events. Although
oral bisphosphonates are generally well tolerated, upper
gastrointestinal complaints are commonly reported in new
users [31]. In addition, with recent concerns for possible
increased risk for femoral shaft fractures after long-term
bisphosphonate use [32], a physician directed drug holiday
may be reasonable for those patients with more than 5 years
of bisphosphonate use, and could account for some of the
non-persistence seen beyond 5 years. While the median
exposure was only 2.2 years, 25% of patients had 5 years of
uninterrupted therapy, and 12% had 9 years of uninterrupted
therapy.
Despite these limitations, our study has several strengths.
We followed more than 450,000 new users of oral bisphosph-
onates for up to 12.8 years. This provided ample follow-up to
characterize both drug switching and treatment reinitiation
patterns. Our results indicate that most patients discontinue
bisphosphonate therapy within 2 years and many experience
more than one extended gap in bisphosphonate use. Although
emerging evidence suggests that after 3–5 years of uninter-
rupted therapy a physician-directed drug holiday may be
appropriate for many patients [24–26], further research is
needed to clarify for which patients this may be suitable. In
addition, we document that the majority of patients are not
exposed to bisphosphonate therapy long enough to be
considered for a physician-directed drug holiday, with a
median length of exposure of only 2 years, and the majority
experiencing one or more extended gaps in therapy.
Osteoporosis is a major public health concern that results
in debilitating fractures. Oral bisphosphonates are first-line
therapy for osteoporosis, and are effective inreducingfracture
risk. Although other therapies are available, including nasal
calcitonin, raloxifene, teriparatide, zoledronic acid, and most
recently, denosumab; these agents are reserved as second or
third line treatment options. Our results not only confirm
findings from other countries by identifying sub-optimal rates
of persistence with oral bisphosphonate, but our findings add
to the literature by identifying the frequency of extended gaps
and rate of return to therapy. We identify that many patients
return to therapy following an extended gap; however, the
clinical impact of this time away from therapy remains
unknown. Further research is needed to identify predictors
of non-persistence and to clarify when and among which
patientsaphysician-directeddrugholidaymaybeappropriate.
Results may then be used to develop effective interventions
that aim to improve the length of persistence and reduce the
frequency of gaps in bisphosphonate therapy. It is through
improved treatment rates among patients at high risk for
fracture that we will we red u c et h ep u b l i ci m p a c to f
osteoporotic fractures.
Acknowledgements This research was supported by research grants
from the Canadian Institutes of Health Research (CIHR) and the
Ontario Ministry of Research Innovation (OMRI). Dr Cadarette holds
a CIHR New Investigator Award in the Area of Aging and
Osteoporosis and an OMRI Early Researcher Award. Andrea Burden
holds the Graduate Department of Pharmaceutical Sciences 2010
Wyeth Pharmaceutical Fellowship in Health Outcomes Research and
the 2010–2011 University of Toronto Bone and Mineral Group
Scholarship (Clinical). Dr. Solomon receives salary support from
Amgen for work on rheumatoid arthritis as well as support from the
Arthritis Foundation, AHRQ, and the NIH (AR 055989, AR 047782)
on osteoporosis and adherence. Dr. Mamdani has received honoraria
for unrelated work from Pfizer, Eli Lilly, and Amgen within the past
3 years. Authors acknowledge Dr. M. Alan Brookhart for insightful
discussions, Brogan Inc. for providing access to drug identification
numbers used to identify eligible drugs, and Jin Luo at the Institute for
Clinical Evaluative Sciences (ICES) for assistance with statistical
analyses. ICES is a non-profit research corporation funded by the
Ontario Ministry of Health and Long-Term Care. The opinions, results
and conclusions are those of the authors and are independent from the
funding sources. No endorsement by CIHR, ICES, OMRI or the
Ontario Ministry of Health and Long-Term Care is intended or should
be inferred.
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
1080 Osteoporos Int (2012) 23:1075–1082Appendix
References
1. Burge R, Dawson-Hughes B, Solomon DH et al (2007)
Incidence and economic burden of osteoporosis-related frac-
tures in the United States, 2005–2025. J Bone Miner Res
22:465–475
2. MacLean C, Newberry S, Maglione M et al (2008) Systematic
review: comparative effectiveness of treatments to prevent
fractures in men and women with low bone density or
osteoporosis. Ann Intern Med 148:197–213
3. Brown JP, Josse RG, Scientific Advisory Council of the
Osteoporosis Society of Canada (2002) 2002 Clinical practice
guidelines for the diagnosis and management of osteoporosis in
Canada. Can Med Assoc J 167(10 Suppl):S1–S34
4. Jaglal SB, Weller I, Mamdani M et al (2005) Population trends in
BMD testing, treatment, and hip and wrist fracture rates: are the
hip fracture projections wrong? J Bone Miner Res 20:898–905
5. Imaz I, Zegarra P, Gonzalez-Enriquez J et al (2010) Poor
bisphosphonate adherence for treatment of osteoporosis increases
fracture risk: systematic review and meta-analysis. Osteoporos
Int 21:1943–1951
6. Siris ES, Selby PL, Saag KG et al (2009) Impact of osteoporosis
treatment adherence on fracture rates in North America and
Europe. Am J Med 122:S3–S13
7. Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM (2010)
Bisphosphonates and osteoporotic fractures: a cross-design syn-
thesis of results among compliant/persistent postmenopausal
women in clinical practice versus randomized controlled trials.
Osteoporos Int 21:1943–1951
8. Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA
(2011) Adherence to osteoporosis drugs and fracture prevention:
no evidence of healthy adherer bias in a frail cohort of seniors.
Osteoporos Int 22:943–954
9. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD
(2007) Patient adherence to osteoporosis medications: problems,
consequences and management strategies. Drugs Aging 24:37–55
10. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ
(2007) Systematic review and meta-analysis of real-world adher-
ence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–
1501
11. Melo M, Qiu F, Sykora K et al (2006) Persistence with
bisphosphonate therapy in older people. J Am Geriatr Soc
54:1015–1016
12. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A
systematic review of persistence and compliance with bisphospho-
nates for osteoporosis. Osteoporos Int 18:1023–1031
13. Cadarette SM, Burden AM (2010) Measuring and improving
adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol
22:397–403
14. Paterson JM, Suleiman A, Hux JE, Bell C (2008) How complete
are drug history profiles that are based on public drug benefit
claims? Can J Clin Pharmacol 15:e108–e116
15. Williams JI, Young W (1996) Appendix 1: A summary of studies
on the quality of health care administrative databases in Canada.
In: Goel V, Williams JI, Anderson GM, Blackstein-Hirsch P,
Fooks C, Naylor CD (eds) Patterns of health care in Ontario, The
ICES Practice Atlas. Canadian Medical Association, Ottawa
16. Richards J, Brown A, Homan C (2001) The data quality study of
the Canadian Discharge Abstract Database. In Proceedings of
Statistics Canada Symposium.
17. Juurlink D, Preyra C, Croxford R et al (2006) Canadian institute
for health information discharge abstract database: a validation
study. In ICES investigative report. Institute for Clinical Evalu-
ative Sciences, Toronto
18. Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson
JM (2011) Osteoporosis quality indicators using healthcare
utilization data. Osteoporos Int 22:1335–1342
19. Ministry of Health and Long-Term Care (2005) Ontario Drug
Benefit formulary/comparative drug index. In. Ministry of Health,
Queen's Printer for Ontario
20. Brookhart MA, Avorn J, Katz JN et al (2007) Gaps in treatment
among users of osteoporosis medications: the dynamics of
noncompliance. Am J Med 120:251–256
21. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compli-
ance and persistence with bisphosphonate dosing regimens among
women with postmenopausal osteoporosis. Curr Med Res Opin
21:1453–1460
22. Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence
with weekly alendronate therapy among postmenopausal women.
Osteoporos Int 17:922–928
Table 3 Medical claims used to identify covariates and exclusion criteria
Variable Coding definition
BMD testing
a Any OHIP claim of: J654, J655, J656, J688, J854, J855, J856, J888, X145, X146, X149, X152, X153, X155 and X157
Paget’s disease
diagnosis
Any of ICD-9-CM = 731.0, 731.1; or ICD-10-CA = M88.x; or OHIP = 731
Fracture history Thoracic vertebral fracture:
Any of ICD-9-CM = 805.2, 805.3 or ICD-10-CA = S22.0x, S22.1x
Hip, humerus, radius or ulna:
Any of ICD-9-CM = 733.11, 733.12, 733.14, 812.x, 813.x, 820.x; or ICD-10-CA = S42.2x, S42.3x, S42.4x, S52.x,
S72.0x, S72.1x, S72.2x; or OHIP = 812, 813, F027, F028, F030
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification; used prior to April 1, 2002; ICD-10-CA International
Classification of Diseases, Tenth Revision, Canada; used since April 1, 2002; OHIP Ontario Health Insurance Plan claims database
aSensitivity=98%, specificity=93% [18]
Osteoporos Int (2012) 23:1075–1082 108123. Solomon DH, Avorn J, Katz JN et al (2005) Compliance with
osteoporosis medications. Arch Intern Med 165:2414–2419
24. Geusens P (2009) Bisphosphonates for postmenopausal osteopo-
rosis: determining duration of treatment. Curr Osteoporos Rep
7:12–17
25. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of
continuing or stopping alendronate after 5 years of treatment. The
Fracture Intervention Trial Long-Term Extension (FLEX): a
randomized trial. JAMA 296:2927–2938
26. Watts NB, Chines A, Olszynski WP et al (2008) Fracture risk
remains reduced one year after discontinuation of risedronate.
Osteoporos Int 19:365–372
27. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008)
Risk of hip fracture after bisphosphonate discontinuation: impli-
cations for a drug holiday. Osteoporos Int 19:1613–1620
28. Cranney A, Guyatt G, Griffith L et al (2002) IX: summary of
meta-analyses of therapies for postmenopausal osteoporosis.
Endocr Rev 23:570–578
29. Jaglal SB (2002) Bone mineral density testing. In: Stewart DE,
Ferris L, Hyman I, Cohen M, Williams JI, Cheung A (eds)
Ontario women's health status report. Institute for Clinical
Evaluative Sciences, Toronto
30. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M
(2000) Using medical services claims to assess injuries in the
elderly: sensitivity of diagnostic and procedure codes for injury
ascertainment. J Clin Epidemiol 53:183–194
31. Cryer B, Bauer DC (2002) Oral bisphosphonates and upper
gastrointestinal tract problems: what is the evidence? Mayo Clin
Proc 77:1031–1043
32. Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric
and diaphyseal femoral fractures: report of a task force of the
American society for bone and mineral research. J Bone Miner
Res 25:2267–2294
33. Cadarette SM, van Wijk BL, Patrick AR, Brookhart MA (2011)
Adherence to pharmacotherapy for hypercholesterolemia, hyperten-
sionand osteoporosis: behavioralinsights.AmJ Pharm Ben,inpress
1082 Osteoporos Int (2012) 23:1075–1082